ALL3
MCID: LKM060
MIFTS: 57

Leukemia, Acute Lymphoblastic 3 (ALL3)

Categories: Blood diseases, Cancer diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Leukemia, Acute Lymphoblastic 3

MalaCards integrated aliases for Leukemia, Acute Lymphoblastic 3:

Name: Leukemia, Acute Lymphoblastic 3 57
Leukemia, Acute Lymphoblastic, Susceptibility to, 3 57 29 6 40 72
B-All 59 55
Precursor B-Cell Acute Lymphoblastic Leukemia/lymphoma 59
Precursor B-Cell Acute Lymphocytic Leukemia/lymphoma 59
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 72
Precursor B-Cell Acute Lymphoblastic Leukemia 59
Precursor B-Cell Acute Lymphocytic Leukemia 59
Precursor B-Cell Lymphoblastic Leukemia 72
Burkitt Lymphoma 72
All3 57

Classifications:



External Ids:

OMIM 57 615545
ICD10 via Orphanet 34 C83.5 C91.0
UMLS via Orphanet 73 C0006413 C1292769
Orphanet 59 ORPHA99860
MedGen 42 C3809874
UMLS 72 C0006413 C0023485 C1292769 more

Summaries for Leukemia, Acute Lymphoblastic 3

MalaCards based summary : Leukemia, Acute Lymphoblastic 3, also known as leukemia, acute lymphoblastic, susceptibility to, 3, is related to leukemia, acute lymphoblastic and myeloid leukemia, and has symptoms including bone pain An important gene associated with Leukemia, Acute Lymphoblastic 3 is PAX5 (Paired Box 5), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Progesterone and Mitoxantrone have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone, and related phenotypes are Decreased viability and Decreased viability

More information from OMIM: 615545

Related Diseases for Leukemia, Acute Lymphoblastic 3

Diseases in the Leukemia, Acute Lymphoblastic family:

Leukemia, Acute Lymphoblastic 2 Leukemia, Acute Lymphoblastic 3

Diseases related to Leukemia, Acute Lymphoblastic 3 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 108)
# Related Disease Score Top Affiliating Genes
1 leukemia, acute lymphoblastic 32.9 RUNX1 PAX5 KMT2A IGH FLT3 ETV6
2 myeloid leukemia 31.2 RUNX1 FLT3 ETV6 BCR ABL1
3 leukemia 31.0 RUNX1 PBX1 HLF FLT3 ETV6 BCR
4 b-cell childhood acute lymphoblastic leukemia 31.0 RUNX1 IKZF1 ETV6
5 lymphocytic leukemia 30.9 RUNX1 PAX5 KMT2A IKZF1 ETV6 BCR
6 myeloproliferative neoplasm 30.9 PDGFRA BCR ABL1
7 leukemia, acute myeloid 30.8 RUNX1 KMT2A FLT3 ETV6 BCR AFF1
8 myelodysplastic syndrome 30.7 RUNX1 KMT2A FLT3 ETV6 ABL1
9 acute leukemia 30.5 TCF3 RUNX1 PAX5 KMT2A FLT3 ETV6
10 b-cell adult acute lymphocytic leukemia 30.2 PBX1 PAX5 IKZF1 ABL1
11 precursor t-cell acute lymphoblastic leukemia 30.1 KMT2A IKZF1 IGH FLT3 ETV6 CDKN2A
12 hematologic cancer 30.0 RUNX1 PAX5 KMT2A IKZF1 FLT3 ETV6
13 childhood leukemia 29.8 TCF3 RUNX1 PBX1 KMT2A ETV6 ABL1
14 leukemia, chronic myeloid 29.3 RUNX1 PDGFRA KMT2A IKZF1 FLT3 ETV6
15 acute t cell leukemia 11.4
16 ring chromosome 21 10.8 KMT2A ETV6
17 philadelphia-negative chronic myeloid leukemia 10.7 BCR ABL1
18 primary hypereosinophilic syndrome 10.7 PDGFRA ETV6
19 myeloid sarcoma 10.6 PAX5 KMT2A FLT3
20 acute myeloid leukemia with t(8;21)(q22;q22) translocation 10.6 RUNX1 FLT3
21 chronic eosinophilic leukemia 10.6 PDGFRA FLT3 ABL1
22 loeffler endocarditis 10.6 PDGFRA ETV6
23 inverted transitional papilloma 10.6 GATA3 CDKN2A
24 8p11 myeloproliferative syndrome 10.6 RUNX1 FLT3 BCR
25 cytogenetically normal acute myeloid leukemia 10.5 KMT2A FLT3
26 atypical chronic myeloid leukemia 10.5 RUNX1 PDGFRA ABL1
27 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 10.5 RUNX1 KMT2A FLT3 ETV6
28 hemophagocytic lymphohistiocytosis 10.4
29 lymphoblastic lymphoma 10.4
30 gastrointestinal stromal tumor 10.4 PDGFRA FLT3 CDKN2A ABL1
31 bartholin's gland disease 10.4 GATA3 CDKN2A
32 chronic myelomonocytic leukemia 10.4 RUNX1 FLT3 ETV6
33 malignant histiocytosis 10.4
34 chromosomal triplication 10.4
35 histiocytic sarcoma 10.4
36 childhood acute lymphocytic leukemia 10.3
37 pancytopenia 10.3
38 hematopoietic stem cell transplantation 10.3
39 mantle cell lymphoma 10.2 PAX5 IGH CDKN2A
40 platelet disorder, familial, with associated myeloid malignancy 10.1 RUNX1 ETV6
41 autoimmune disease 10.1
42 burkitt lymphoma 10.1
43 leukemia, acute monocytic 10.1
44 leukemia, chronic lymphocytic 10.1
45 down syndrome 10.1
46 fanconi anemia, complementation group d2 10.1
47 myasthenia gravis 10.1
48 myelofibrosis 10.1
49 thymoma, familial 10.1
50 isolated growth hormone deficiency, type iii, with agammaglobulinemia 10.1

Graphical network of the top 20 diseases related to Leukemia, Acute Lymphoblastic 3:



Diseases related to Leukemia, Acute Lymphoblastic 3

Symptoms & Phenotypes for Leukemia, Acute Lymphoblastic 3

Clinical features from OMIM:

615545

UMLS symptoms related to Leukemia, Acute Lymphoblastic 3:


bone pain

GenomeRNAi Phenotypes related to Leukemia, Acute Lymphoblastic 3 according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.99 BCR
2 Decreased viability GR00173-A 9.99 FLT3 PDGFRA
3 Decreased viability GR00221-A-1 9.99 ABL1 CDKN2A FLT3 PDGFRA PIP4K2A
4 Decreased viability GR00221-A-2 9.99 ABL1 BCR
5 Decreased viability GR00221-A-3 9.99 ABL1 CDKN2A PDGFRA
6 Decreased viability GR00221-A-4 9.99 CDKN2A FLT3 PDGFRA PIP4K2A BCR
7 Decreased viability GR00301-A 9.99 PIP4K2A BCR
8 Decreased viability GR00342-S-1 9.99 ABL1
9 Decreased viability GR00342-S-2 9.99 ABL1
10 Decreased viability GR00342-S-3 9.99 ABL1 BCR
11 Decreased viability GR00402-S-2 9.99 ABL1 CDKN2A FLT3 PDGFRA PIP4K2A BCR

MGI Mouse Phenotypes related to Leukemia, Acute Lymphoblastic 3:

46 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.41 ABL1 AFF1 AUTS2 BCR CDKN2A ETV6
2 cellular MP:0005384 10.4 ABL1 AUTS2 BCR CDKN2A ETV6 FLT3
3 hematopoietic system MP:0005397 10.34 ABL1 AFF1 BCR CDKN2A ETV6 FLT3
4 behavior/neurological MP:0005386 10.32 ABL1 AFF1 AUTS2 BCR CDKN2A HLF
5 cardiovascular system MP:0005385 10.31 ABL1 AUTS2 CDKN2A ETV6 GATA3 HLF
6 endocrine/exocrine gland MP:0005379 10.3 ABL1 AFF1 AUTS2 CDKN2A ETV6 FLT3
7 immune system MP:0005387 10.3 ABL1 AFF1 BCR CDKN2A ETV6 FLT3
8 mortality/aging MP:0010768 10.3 ABL1 AFF1 AUTS2 BCR CDKN2A ETV6
9 homeostasis/metabolism MP:0005376 10.26 ABL1 BCR CDKN2A ETV6 FLT3 GATA3
10 embryo MP:0005380 10.24 ABL1 AUTS2 CDKN2A ETV6 GATA3 KMT2A
11 digestive/alimentary MP:0005381 10.15 ABL1 BCR CDKN2A ETV6 GATA3 IKZF1
12 liver/biliary system MP:0005370 10.1 ABL1 AUTS2 BCR CDKN2A HLF IKZF1
13 nervous system MP:0003631 10.07 ABL1 AFF1 AUTS2 BCR CDKN2A GATA3
14 neoplasm MP:0002006 10.06 AUTS2 CDKN2A ETV6 FLT3 IKZF1 KMT2A
15 integument MP:0010771 10.03 CDKN2A ETV6 GATA3 IKZF1 KMT2A PBX1
16 no phenotypic analysis MP:0003012 9.93 AFF1 AUTS2 CDKN2A ETV6 FLT3 GATA3
17 normal MP:0002873 9.73 ABL1 BCR ETV6 GATA3 HLF KMT2A
18 skeleton MP:0005390 9.28 ABL1 CDKN2A FLT3 GATA3 KMT2A PAX5

Drugs & Therapeutics for Leukemia, Acute Lymphoblastic 3

Drugs for Leukemia, Acute Lymphoblastic 3 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 600)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
2
Mitoxantrone Approved, Investigational Phase 4 65271-80-9 4212
3
Teniposide Approved Phase 4 29767-20-2 34698
4
Ethanol Approved Phase 4 64-17-5 702
5
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
6
Methadone Approved, Illicit Phase 4 76-99-3 4095
7
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
8
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
9
Rifapentine Approved, Investigational Phase 4 61379-65-5 6323497
10
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
11
leucovorin Approved Phase 4 58-05-9 143 6006
12
rituximab Approved Phase 4 174722-31-7 10201696
13
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
14 Estrogens Phase 4
15 Progestins Phase 4
16 Antitubercular Agents Phase 4
17 Narcotics Phase 4
18 Central Nervous System Depressants Phase 4
19 Analgesics, Opioid Phase 4
20 Respiratory System Agents Phase 4
21 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
22 Antitussive Agents Phase 4
23 Lipid Regulating Agents Phase 4
24 Narcotic Antagonists Phase 4
25 Hypolipidemic Agents Phase 4
26 Folic Acid Antagonists Phase 4
27 Nucleic Acid Synthesis Inhibitors Phase 4
28 Vitamin B9 Phase 4
29 Folate Phase 4
30 Vitamin B Complex Phase 4
31 Immunosuppressive Agents Phase 4
32 Dermatologic Agents Phase 4
33 Antimetabolites, Antineoplastic Phase 4
34 Antimetabolites Phase 4
35 Antineoplastic Agents, Immunological Phase 4
36
Clavulanate Approved, Vet_approved Phase 3 58001-44-8 5280980
37
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
38
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613
39 Orange Approved Phase 3
40
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
41
Hydroxyurea Approved Phase 3 127-07-1 3657
42
Tranexamic Acid Approved Phase 2, Phase 3 1197-18-8 5526
43
Melphalan Approved Phase 3 148-82-3 460612 4053
44
Dalteparin Approved Phase 3 9005-49-6
45
Acyclovir Approved Phase 3 59277-89-3 2022
46
Ofloxacin Approved Phase 3 82419-36-1 4583
47
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
48
Carmustine Approved, Investigational Phase 3 154-93-8 2578
49
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
50
Tazobactam Approved Phase 3 89786-04-9 123630

Interventional clinical trials:

(show top 50) (show all 863)
# Name Status NCT ID Phase Drugs
1 A Multicenter Study to Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma Patients With Isolated Anti-HBc-positivity Who Will be Treated With Rituximab Based Chemotherapy Unknown status NCT02585947 Phase 4 Tenofovir
2 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
3 Optimal Length of Progesterone Supplementation Before the Transfer of Cryopreserved (Frozen)-Thawed Day 3 Embryos in an Artificial Cycle With Exogenous Estrogen and Progesterone Unknown status NCT01940653 Phase 4 Progesterone
4 Comparing Dexlansoprazole With Double-dose Lansoprazole to Achieve Sustained Symptomatic Response in Overweight and Obesity Patients With Reflux Esophagitis in Los Angeles Grades A & B Unknown status NCT02759393 Phase 4 Dexlansoprazole;Lansoprazole
5 Multicenter Study to Optimise Therapy of B-ALL, Burkitt's NHL and High-Grade Non-Hodgkin's Lymphoma in Adults (Amend 7) Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
6 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
7 Multicenter Trial for Treatment of Acute Lymphoblastic Leukemia in Adults (05/93) Completed NCT00199069 Phase 4 Asparaginase;Vincristine;Daunorubicin, Adriamycin;Cyclophosphamide;Ifosfamide;Cytarabine;Mitoxantrone;Methotrexate;6-Mercaptopurine;6-Thioguanine;VM26;Dexamethasone / Prednisolone
8 ALL-REZ BFM 2002: Protocol for the Treatment of Children With Relapsed Acute Lymphoblastic Leukemia Completed NCT00114348 Phase 4
9 A PHASE 4, OPEN-LABEL, RANDOMIZED STUDY OF TWO INOTUZUMAB OZOGAMICIN DOSE LEVELS IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA ELIGIBLE FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION AND WHO HAVE RISK FACTOR(S) FOR VENO-OCCLUSIVE DISEASE Recruiting NCT03677596 Phase 4 inotuzumab ozogamicin-dose level 2;Inotuzumab ozogamicin-dose level 1
10 Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia Recruiting NCT02618109 Phase 4
11 Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings Recruiting NCT03089983 Phase 4 Naltrexone;Methadone;Isoniazid;Rifapentine
12 Timed Intercourse Versus Intrauterine Insemination in Infertile Patients Undergoing Gonadotropin Ovarian Stimulation Suspended NCT00502281 Phase 4 highly purified urinary FSH
13 Efficacy of MabThera in Patients With Rheumatoid Arthritis, by Measurement of Disease Parameters Through Magnetic Resonance of the Hand (RESONAR Study) Terminated NCT01117129 Phase 4 rituximab [MabThera/Rituxan];placebo;methotrexate;rituximab [Mabthera/Rituxan]
14 LMBA02 Protocol for Patients With a Burkitt Lymphoma Unknown status NCT00180882 Phase 3 rituximab
15 The Utility of LymphoScan Imaging in the Dectection of Residual Tumor After Chemotherapy and/or Radiotherapy in Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
16 The Utility of LymphoScan Imaging in the Localization and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
17 A Randomized Phase III Study to Assess Intensification of the Conditioning Regimen for Allogenic Stem Cell Transplantation (ALLO-SCT) for Leukemia or Myelodysplastic Syndrome With a High Risk of Relapse Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
18 Randomised Trial Comparing Chemotherapy Mit CHOEP (Cyclophosphamid, Doxorubicin, Vincristin, Etoposid Und Prednison) In 21-Day Intervals In Standard And Escalated Doses In Patients Aged 18-60 Years Of Age With Aggresive Non-Hodgkin-Lymphomas Favourable Prognoses Unknown status NCT00053768 Phase 3 EPOCH regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
19 Randomised Study Comparing 6 And 8 Cycles Of Chemotherapy With CHOP ( Cyclophosphamide, Doxorubicin, Vincristine And Prednisone) At 14-Day Intervals (CHOP-14), Both With Or Without The Monoclonal Anti-CD20 Antibody Rituximab In Patients Aged 61 To 80 Years With Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
20 A Prospective Randomised Phase III Trial of Early Hospital Discharge Versus Standard Inpatient Management of Cancer Patients With Low-Risk Febrile Neutropenia Receiving Oral Antibiotics. Oral Antibiotics for Neutropenic Sepsis Giving Early Hospital Discharge [ORANGE] Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
21 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
22 A European Randomized Multicenter Study of Interferon Alfa-2b Versus No Treatment After Intensive Therapy and Autologous Hematopoietic Stem Cell Transplantation for Relapsing Lymphoma Patients (Non-Hodgkin Lymphomas and Hodgkin's Disease) Unknown status NCT00003924 Phase 3
23 A Double-bline Safety and Efficacy Study Comparing Pad-gauze With Tranexamic Acid (Hemostopan™) to a Regular Pad-gauze in Controlling Bleeding in Patients on Hemodialysis. Unknown status NCT01854476 Phase 2, Phase 3
24 PROSPECTIVE CONTROLLED STUDY FOR THE OPTIMIZATION OF THERAPY IN CHRONIC MYELOID LEUKEMIA (CML): MULTICENTRIC STUDY FOR THE EVALUATION OF INTERFERON ALPHA VS ALLOGENIC BM TRANSPLANTATION WITH CHEMOTHERAPY IN CML Unknown status NCT00002771 Phase 3 busulfan;cytarabine;hydroxyurea;idarubicin
25 A Pilot Study of Dose Intensification of Methotrexate in Patients With Advanced-Stage (III/IV) Small Non-Cleaved Cell Non-Hodgkins Lymphoma and B-Cell All Completed NCT00005977 Phase 3 cyclophosphamide;cytarabine;dexamethasone;doxorubicin hydrochloride;etoposide;ifosfamide;leucovorin calcium;methotrexate;vincristine sulfate
26 A RANDOMIZED PROSPECTIVE TRIAL OF CHOP VERSUS MCOP IN ELDERLY PATIENTS WITH INTERMEDIATE AND HIGH GRADE NON-HODGKIN'S LYMPHOMA (AGED 65 YEARS AND OVER) Completed NCT00002576 Phase 3 cyclophosphamide;doxorubicin hydrochloride;mitoxantrone hydrochloride;prednisolone;vincristine sulfate
27 A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters Completed NCT00006083 Phase 3 Fragmin
28 Does Hypericum Reduce Fatigue in Cancer Patients on Chemotherapy? A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Completed NCT00005805 Phase 3
29 A Randomized, Prospective Double-Blind, Placebo-Controlled Trial of Prophylactic Oral Levofloxacin Following Chemotherapy for Lymphoma and Solid Tumors Completed NCT00005590 Phase 3 levofloxacin
30 Vancomycin Versus Placebo in Persistently Febrile Granulocytopenic Patients Given Piperacillin/Tazobactam Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
31 Randomized Study Comparing 4 and 6 Cycles of Chemotherapy With CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) at 21-day Intervals, Both With 6 Cycles of Immunotherapy With the Monoclonal Anti-CD20-Positive B-Cell Lymphoma Aged 18-60 Years Having no Risk Factor (Age-Adjusted IPI=0) and No Large Tumor Mass (Diameter <7,5cm) [FLYER 6-6-6-4 Study] Completed NCT00278421 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
32 A Double-Blind Study Of Nutritional Intervention For The Treatment Of Cancer Cachexia Using Juven® Nutritional Supplement Completed NCT00053053 Phase 3
33 A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Cancer Patients With Chemotherapy-Associated Anemia Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
34 Total Body Irradiation, Etoposide, Cyclophosphamide and Autologous Peripheral Blood Stem Cell Transplantation Followed by Randomization to Therapy With Interleukin-2 Versus Observation for Patients With Non-Hodgkin's Lymphoma Completed NCT00002649 Phase 3 cyclophosphamide;etoposide
35 Phase III Trial of T Lymphocyte Depletion by Elutriation and CD34 Add-Back for Allogeneic Bone Marrow Transplantation Completed NCT00265837 Phase 3
36 Music Video and Adolescent/Young Adult Resilience During Transplant Completed NCT00305851 Phase 3
37 A Randomized Double-Blind Placebo-Controlled Phase III Study To Evaluate The Safety And Efficacy Of Palivizumab Combined With Aerosolized Ribavirin Compared To Ribavirin Alone To Treat RSV Pneumonia In Patients With Bone Marrow Transplants (BMT) Completed NCT00014391 Phase 3 ribavirin
38 Phase III Study of Captopril in Patients Undergoing Autologous Bone Marrow/Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
39 SWOG-9704 A Randomized Phase III Trial Comparing Early High Dose Chemoradiotherapy and an Autologous Stem Cell Transplant to Conventional Dose CHOP Chemotherapy Plus Rituximab for CD20+ B Cell Lymphomas (With Possible Late Autologous Stem Cell Transplant) for Patients With Diffuse Aggressive Non-Hodgkin's Lymphoma in the High-Intermediate and High Risk International Classification Prognostic Groups Completed NCT00004031 Phase 3 CHOP regimen;carmustine;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
40 A Randomized, Comparative Study of Itraconazole Versus Fluconazole for Prevention of Aspergillus Infections in Peripheral Blood Stem Cell and Marrow Transplant Recipients Completed NCT00003883 Phase 3 fluconazole;itraconazole
41 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
42 Randomized Study Comparing an Immuno-Chemotherapy With 6 Cycles of the Monoclonal Anti-CD20 Antibody Rituximab in Combination With 6 Cycles of Chemotherapy With CHOP ( Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) at 21-day Intervals or 14-day Intervals, Both With or Without Consolidating Radiotherapy or Large Tumour Masses (≥7.5 cm) and/or Extranodal Involvement in Patients With Aggressive CD20 B-Cell Lymphoma Aged 18 to 60 Years With Age-Adjusted IPI=1 (All) or IPI=0 With a Large Tumour Mass (≥7.5 cm) [UNFOLDER 21/14 Study] Completed NCT00278408 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
43 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
44 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
45 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
46 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
47 A Phase III Multicenter Study of Cytomegalovirus Prophylaxis With Valacyclovir for the Prevention of Serious Fungal and Bacterial Infections Among Cytomegalovirus Seronegative Recipients of Cytomegalovirus Seropositive Sx Stem Cell Transplants Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
48 Randomized Placebo Controlled Double Blind Study of Restasis Versus Placebo in Primary Prevention of Ocular GVHD After Allogeneic Stem Cell Transplantation Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
49 A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
50 A Randomized Multicentre Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies Completed NCT00438958 Phase 3

Search NIH Clinical Center for Leukemia, Acute Lymphoblastic 3

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Cyclophosphamide

Genetic Tests for Leukemia, Acute Lymphoblastic 3

Genetic tests related to Leukemia, Acute Lymphoblastic 3:

# Genetic test Affiliating Genes
1 Leukemia, Acute Lymphoblastic, Susceptibility to, 3 29 PAX5

Anatomical Context for Leukemia, Acute Lymphoblastic 3

MalaCards organs/tissues related to Leukemia, Acute Lymphoblastic 3:

41
B Cells, T Cells, Bone, Bone Marrow, B Lymphoblasts, Myeloid, Breast

Publications for Leukemia, Acute Lymphoblastic 3

Articles related to Leukemia, Acute Lymphoblastic 3:

(show top 50) (show all 5517)
# Title Authors PMID Year
1
A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. 38 8 71
24013638 2013
2
PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. 38 8
30643249 2019
3
Wide diversity of PAX5 alterations in B-ALL: a Groupe Francophone de Cytogenetique Hematologique study. 9 38
20160164 2010
4
[Prognostic significance of TEL/AML1 rearrangement and its additional genetic changes in Korean childhood precursor B-acute lymphoblastic leukemia]. 9 38
20197715 2010
5
Expression profiling of transcription factors in B- or T-acute lymphoblastic leukemia/lymphoma and burkitt lymphoma: usefulness of PAX5 immunostaining as pan-Pre-B-cell marker. 9 38
20023257 2010
6
ABL1 gene deletion without BCR/ABL1 rearrangement in a young adolescent with precursor B-cell acute lymphoblastic leukemia: clinical study and literature review. 9 38
20082857 2010
7
Homozygous deletion of CDKN2A (p16, p14) and CDKN2B (p15) genes is a poor prognostic factor in adult but not in childhood B-lineage acute lymphoblastic leukemia: a comparative deletion and hypermethylation study. 9 38
19837270 2009
8
[Characteristics of fusion gene and immunophenotype in MLL gene rearrangement positive childhood acute lymphoblastic leukemia]. 9 38
19840468 2009
9
Identification of new microRNA genes and aberrant microRNA profiles in childhood acute lymphoblastic leukemia. 9 38
18923441 2009
10
Very early onset of an acute myeloid leukemia in an adult patient with B-cell lymphoblastic leukemia. 9 38
19143872 2009
11
[Gene expression profile of human TGF-beta signal transduction pathway of B cell type acute lymphocytic leukemia]. 9 38
18718051 2008
12
Frequent but nonrandom expression of myeloid markers on de novo childhood acute lymphoblastic leukemia. 9 38
17434163 2007
13
[Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases]. 9 38
17430665 2007
14
Immunophenotypic subtyping of leukemic cells from Iranian patients with acute lymphoblastic leukaemia: association to disease outcome. 9 38
17652839 2007
15
CXC chemokine ligand 13 and CC chemokine ligand 19 cooperatively render resistance to apoptosis in B cell lineage acute and chronic lymphocytic leukemia CD23+CD5+ B cells. 9 38
17082584 2006
16
Lineage determination of CD20- B-Cell neoplasms: an immunohistochemical study. 9 38
16938666 2006
17
Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapy. 9 38
16939815 2006
18
Chemokine receptor expression and function in childhood acute lymphoblastic leukemia of B-lineage. 9 38
16118018 2006
19
[Expression of the transcription factor PAX5 in childhood acute leukemic cells]. 9 38
16584581 2006
20
Troglitazone inhibits cell growth and induces apoptosis of B-cell acute lymphoblastic leukemia cells with t(14;18). 9 38
16809887 2006
21
Detection of FLT3 gene and FLT3/ITD mutation by polymerase chain reaction-single-strand conformation polymorphism in patients with acute lymphoblastic leukemia. 9 38
16234090 2005
22
[Detection of minimal residual disease in B lineage acute lymphoblastic leukemia by 4-color flow cytometry]. 9 38
16185473 2005
23
Interphase FISH to detect PBX1/E2A fusion resulting from the der(19)t(1;19)(q23;p13.3) or t(1;19)(q23;p13.3) in paediatric patients with acute lymphoblastic leukaemia. 9 38
15801954 2005
24
PEG10 activation by co-stimulation of CXCR5 and CCR7 essentially contributes to resistance to apoptosis in CD19+CD34+ B cells from patients with B cell lineage acute and chronic lymphocytic leukemia. 9 38
16225771 2004
25
[CXCR4 expression in B-lineage acute lymphocyte leukemia and its significance]. 9 38
15363127 2004
26
Mature B-cell acute lymphoblastic leukemia with t(9;11) translocation: a distinct subset of B-cell acute lymphoblastic leukemia. 9 38
15098014 2004
27
[Analysis of immunophenotype of B-lineage acute lymphoblastic leukemia cells by 4-color flow cytometry]. 9 38
12744734 2003
28
[Immunophenotypic features of bcr/abl fusion transcript-positive B-lineage acute lymphoblast leukemia]. 9 38
12744735 2003
29
Analysis of p16 gene mutations and deletions in childhood acute lymphoblastic leukemias. 9 38
12870051 2003
30
T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. 9 38
12393484 2003
31
Determination of myeloid antigen expression on childhood acute lymphoblastic leukaemia cells: discrepancies using different monoclonal antibody clones. 9 38
11697497 2001
32
Loss of p73 gene expression in lymphoid leukemia cell lines is associated with hypermethylation. 9 38
11337015 2001
33
Determination of myeloid antigen expression on childhood acute lymphoblastic leukaemia cells: discrepancies using different monoclonal antibody clones. 9 38
11699224 2001
34
Differential expression of chemokine receptors in B cell malignancies. 9 38
11368435 2001
35
Adult precursor B-ALL with BCR/ABL gene rearrangements displays a unique immunophenotype based on the pattern of CD10, CD34, CD13 and CD38 expresssion. 9 38
11237064 2001
36
Shifts in expression of immunological cell markers in relapsed acute leukemia. 9 38
11583283 2001
37
[Classification of acute leukemias according to the first latin-american consensus conference for the immunophenotyping of leukemias]. 9 38
11195181 2000
38
Expression of adhesion molecules in childhood B-lineage-cell neoplasms. 9 38
10979212 2000
39
Acute lymphoblastic leukaemia: correlation between morphological/immunohistochemical and molecular biological findings in bone marrow biopsy specimens. 9 38
10889907 2000
40
Hypermethylation of p16 and p15 genes and RB protein expression in acute leukemia. 9 38
10634644 2000
41
[Homozygous deletion and methylation of p16 and p15 gene in acute leukemia]. 9 38
11721412 1999
42
Loss of p73 gene expression in leukemias/lymphomas due to hypermethylation. 9 38
10419905 1999
43
p16/MTS1/INK4A gene is frequently inactivated by hypermethylation in childhood acute lymphoblastic leukemia with 11q23 translocation. 9 38
10360377 1999
44
Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children. 9 38
10233379 1999
45
Myeloperoxidase gene expression in infant leukemia: a Pediatric Oncology Group Study. 9 38
9638984 1998
46
Comparison of the effects of AcSDKP, thymosin beta4, macrophage inflammatory protein 1alpha and transforming growth factor beta on human leukemic cells. 9 38
9477130 1997
47
Methylation of the multi tumor suppressor gene-2 (MTS2, CDKN1, p15INK4B) in childhood acute lymphoblastic leukemia. 9 38
9399648 1997
48
C-kit receptors in childhood malignant lymphoblastic cells. 9 38
9168431 1997
49
Application of long PCR to detect t(8;14)(q24;q32) translocations in childhood Burkitt's lymphoma and B-ALL. 9 38
9187426 1997
50
Coexpression of cell-surface immunoglobulin (sIg), terminal deoxynucleotidyl transferase (TdT) and recombination activating gene 1 (RAG-1): two cases and derived cell lines. 9 38
8683996 1996

Variations for Leukemia, Acute Lymphoblastic 3

ClinVar genetic disease variations for Leukemia, Acute Lymphoblastic 3:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 PAX5 NM_016734.3(PAX5): c.547G> A (p.Gly183Ser) single nucleotide variant risk factor rs398123063 9:37002702-37002702 9:37002705-37002705
2 PAX5 NM_016734.3(PAX5): c.1013-1G> A single nucleotide variant Uncertain significance rs1554646594 9:36846927-36846927 9:36846930-36846930

Expression for Leukemia, Acute Lymphoblastic 3

Search GEO for disease gene expression data for Leukemia, Acute Lymphoblastic 3.

Pathways for Leukemia, Acute Lymphoblastic 3

GO Terms for Leukemia, Acute Lymphoblastic 3

Cellular components related to Leukemia, Acute Lymphoblastic 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.7 TCF3 RUNX1 PIP4K2A PBX1 PAX5 KMT2A
2 protein-containing complex GO:0032991 9.55 PDGFRA IKZF1 FLT3 BCR ABL1
3 nucleus GO:0005634 9.55 TCF3 RUNX1 PIP4K2A PDGFRA PBX1 PAX5

Biological processes related to Leukemia, Acute Lymphoblastic 3 according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.98 TCF3 RUNX1 KMT2A GATA3 CDKN2A
2 cell differentiation GO:0030154 9.91 TCF3 PBX1 PAX5 FLT3 ETV6 ABL1
3 regulation of transcription, DNA-templated GO:0006355 9.9 TCF3 RUNX1 PBX1 PAX5 KMT2A HLF
4 protein autophosphorylation GO:0046777 9.78 PDGFRA FLT3 BCR ABL1
5 positive regulation of transcription by RNA polymerase II GO:0045944 9.7 TCF3 RUNX1 PBX1 PAX5 KMT2A IKZF1
6 peptidyl-tyrosine phosphorylation GO:0018108 9.69 PDGFRA FLT3 ABL1
7 positive regulation of endothelial cell migration GO:0010595 9.67 GATA3 FOXP1 ABL1
8 thymus development GO:0048538 9.63 PBX1 GATA3 ABL1
9 transcription by RNA polymerase II GO:0006366 9.62 PAX5 KMT2A HLF GATA3
10 regulation of actin cytoskeleton reorganization GO:2000249 9.58 PDGFRA ABL1
11 animal organ morphogenesis GO:0009887 9.58 PDGFRA PBX1 PAX5
12 positive regulation of histone H3-K4 methylation GO:0051571 9.57 KMT2A AUTS2
13 hematopoietic stem cell proliferation GO:0071425 9.56 RUNX1 ETV6
14 cell activation GO:0001775 9.55 PDGFRA GATA3
15 regulation of B cell receptor signaling pathway GO:0050855 9.54 RUNX1 PAX5
16 platelet-derived growth factor receptor signaling pathway GO:0048008 9.54 PDGFRA BCR ABL1
17 negative regulation of ubiquitin-protein transferase activity GO:0051444 9.52 CDKN2A ABL1
18 embryonic hemopoiesis GO:0035162 9.43 PBX1 KMT2A GATA3
19 regulation of hematopoietic stem cell differentiation GO:1902036 9.02 TCF3 RUNX1 KMT2A GATA3 ABL1

Molecular functions related to Leukemia, Acute Lymphoblastic 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 sequence-specific DNA binding GO:0043565 9.88 PBX1 HLF GATA3 FOXP1 ETV6
2 DNA-binding transcription factor activity, RNA polymerase II-specific GO:0000981 9.85 TCF3 RUNX1 PBX1 PAX5 KMT2A IKZF1
3 transcription regulatory region DNA binding GO:0044212 9.76 RUNX1 KMT2A IKZF1 GATA3
4 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.73 TCF3 RUNX1 PBX1 PAX5 GATA3 ETV6
5 DNA binding GO:0003677 9.73 TCF3 RUNX1 PBX1 PAX5 KMT2A IKZF1
6 RNA polymerase II regulatory region sequence-specific DNA binding GO:0000977 9.72 RUNX1 PBX1 HLF GATA3 ETV6
7 protein tyrosine kinase activity GO:0004713 9.54 PDGFRA FLT3 ABL1
8 vascular endothelial growth factor-activated receptor activity GO:0005021 9.4 PDGFRA FLT3
9 DNA-binding transcription factor activity GO:0003700 9.36 TCF3 RUNX1 PBX1 PAX5 KMT2A IKZF1
10 protein binding GO:0005515 10.36 TCF3 RUNX1 PDGFRA PBX1 PAX5 KMT2A

Sources for Leukemia, Acute Lymphoblastic 3

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....